This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
The study participants are female patients with breast cancer receiving Anthracycline based chemotherapy. They will be divided into 2 groups , the first group will receive 40 mg oral atorvastatin through out the study , while the other group will receive a placebo. Full echocardiographic study including 3D echocardiography will be done to all patients before starting their chemotherapy and after 6 months.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Enrollment
100
40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
Placebo
Ain Shams University hospitals
Cairo, Egypt
RECRUITINGIncidence of cancer therapy related cardiac dysfunction among the two groups
cancer therapy related cardiac dysfunction defined as drop in ejection fraction more than 10% and to a value below 53% assessed by 3D echocardiography
Time frame: Six months
Changes in left ventricular ejection fraction assessed by 3D echocardiography among the two groups
Time frame: Six months
Changes in left ventricular volumes assessed by 3D echocardiography among the two groups
Time frame: Six months
Changes in left ventricular diastolic function among the two groups
Time frame: Six months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.